Patent
Polymeric sealant for medical use
| العنوان: | Polymeric sealant for medical use |
|---|---|
| Patent Number: | 9,119,896 |
| تاريخ النشر: | September 01, 2015 |
| Appl. No: | 13/323636 |
| Application Filed: | December 12, 2011 |
| مستخلص: | The invention provides a polymeric medical sealant. The medical sealant is useful for application to the tonsils and adenoids, wherein the sealant performs at least one of the following functions, a) inhibit the colonization of bacteria, b) inhibit the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing. f) promotion of healing, and g) reduction of pain. |
| Inventors: | Hissong, James Britton (Jacksonville, FL, US); Oliver, Dana A. (Jacksonville, FL, US); Lewis, Cecil O. (Jacksonville, FL, US); Saunier, Janis (Ponte Vedra Beach, FL, US); Myntti, Matthew F. (St. Augustine, FL, US) |
| Assignees: | Medtronic Xomed, Inc. (Jacksonville, FL, US) |
| Claim: | 1. A method of postoperative treatment for use after removal of the tonsils or adenoids which comprises the step of applying to throat tissue a powder which hardens and crosslinks after application to form a bioresorbable or biodegradable polymeric medical sealant that adheres to such tissue and performs at least one of the following functions: a) inhibits the colonization of bacteria, b) inhibits the binding of bacteria to tissue, c) reduces tissue morbidity, d) hemostasis, e) coats and protects tissue during healing, f) promotes healing, or g) reduces pain, wherein the powder comprises a silk, silk-elastin, poly(malic acid), polyhydroxybutyrate, polyhydroxyvalerate, chitin, chitosan, oxidized cellulose, or agar polymer, copolymer, terpolymer, blend or mixture thereof. |
| Claim: | 2. The method of treatment according to claim 1 wherein the application of the powder reduces pain in tissue to which it is applied during treatment or postoperative healing. |
| Claim: | 3. The method of treatment according to claim 1 wherein the powder further includes at least one therapeutic agent selected from the group consisting of analgesics, antihistamines, anti-infective agents, anti-fungal agents, biostatic compositions, anti-inflammatory agents, anticholingerics, antineoplastic agents, cytokines, decongestants, vitamins, peptides, proteins, nucleic acids, immunosuppressors, vasoconstrictors and mixtures thereof. |
| Claim: | 4. The method of treatment according to claim 1 wherein the powder has a colorant that provides visual confirmation of the sealant present at a surgical site. |
| Claim: | 5. The method of treatment according to claim 1 wherein the sealant inhibits the colonization of bacteria. |
| Claim: | 6. The method of treatment according to claim 1 wherein the sealant inhibits the binding of bacteria to tissue. |
| Claim: | 7. The method of treatment according to claim 1 wherein the powder reduces tissue morbidity in tissue to which it is applied. |
| Claim: | 8. The method of treatment according to claim 1 wherein the sealant reduces bleeding. |
| Claim: | 9. The method of treatment according to claim 1 wherein the sealant coats and protects tissue during healing. |
| Claim: | 10. The method of treatment according to claim 1 wherein the sealant promotes healing. |
| Claim: | 11. The method of treatment according to claim 1 wherein the sealant performs hemostasis, promotes healing and reduces pain. |
| Claim: | 12. The method of treatment according to claim 1 wherein the sealant is a crosslinked silk or silk-elastin polymer, or a copolymer, terpolymer, blend, or mixture thereof. |
| Claim: | 13. The method of treatment according to claim 1 wherein the sealant is a crosslinked chitosan polymer, or a copolymer, terpolymer, blend, or mixture thereof. |
| Claim: | 14. The method of treatment according to claim 1 wherein the powder comprises a crosslinking material. |
| Claim: | 15. The method of treatment according to claim 1 wherein the sealant is a polyhydroxybutyrate or polyhydroxyvalerate polymer, or a copolymer, terpolymer, blend, or mixture thereof. |
| Claim: | 16. The method of treatment according to claim 1 wherein the sealant is a chitin polymer, or a copolymer, terpolymer, blend, or mixture thereof. |
| Claim: | 17. The method of treatment according to claim 1 wherein the sealant is a poly(malic acid), or a copolymer, terpolymer, blend, or mixture thereof. |
| Claim: | 18. The method of treatment according to claim 1 comprising applying the powder in atomized form. |
| Claim: | 19. The method of treatment according to claim 1 wherein the powder forms a pliable barrier upon application. |
| Claim: | 20. The method of treatment according to claim 1 wherein the sealant is a viscoelastic material. |
| Claim: | 21. The method of treatment according to claim 1 wherein the sealant has a residence time of at least one day. |
| Claim: | 22. The method of treatment according to claim 1 wherein the sealant has a residence time of at least one week. |
| Claim: | 23. The method of treatment according to claim 1 wherein the sealant has a residence time of at least one month. |
| Claim: | 24. The method of treatment according to claim 1 wherein the sealant is an oxidized cellulose polymer, or a copolymer, terpolymer, blend, or mixture thereof. |
| Claim: | 25. The method of treatment according to claim 1 wherein the sealant is an agar polymer, or a copolymer, terpolymer, blend, or mixture thereof. |
| Patent References Cited: | 3422186 January 1969 Sasmor 4002775 January 1977 Kabara 4107328 August 1978 Michaels 4323551 April 1982 Parran, Jr. 4427650 January 1984 Stroetmann 4427651 January 1984 Stroetmann 4442655 April 1984 Stroetmann 4662829 May 1987 Nehring 4851521 July 1989 Della Valle et al. 4902281 February 1990 Avoy 5017229 May 1991 Burns et al. 5145664 September 1992 Thompson 5166331 November 1992 Della Valle et al. 5208257 May 1993 Kabara 5229103 July 1993 Eagle et al. 5246964 September 1993 Ueno 5290552 March 1994 Sierra et al. 5326567 July 1994 Capelli 5336163 August 1994 DeMane et al. 5388574 February 1995 Ingebrethsen 5442053 August 1995 Della Valle et al. 5480658 January 1996 Melman 5575815 November 1996 Slepian et al. 5601594 February 1997 Best 5631241 May 1997 Della Valle et al. 5644049 July 1997 Giusti et al. 5662913 September 1997 Capelli 5676964 October 1997 Della Valle et al. 5693065 December 1997 Rains, III 5709546 January 1998 Waggoner 5716981 February 1998 Hunter et al. 5739176 April 1998 Dunn et al. 5763410 June 1998 Edwardson et al. 5773033 June 1998 Cochrum et al. 5895781 April 1999 Neumiller et al. 5910420 June 1999 Tuompo et al. 5925334 July 1999 Rubin et al. 5968542 October 1999 Tipton 6001870 December 1999 Henkel 6013657 January 2000 Lavon et al. 6063061 May 2000 Wallace et al. 6071305 June 2000 Brown et al. 6129761 October 2000 Hubbell 6143330 November 2000 Aaltonen et al. 6156294 December 2000 Mautone 6156792 December 2000 Hatton et al. 6200587 March 2001 Soe et al. 6203822 March 2001 Schlesinger et al. 6224857 May 2001 Romeo et al. 6248371 June 2001 Domenico 6284804 September 2001 Singh et al. 6312725 November 2001 Wallace 6342251 January 2002 Illum et al. 6372229 April 2002 Ollerenshaw et al. 6375963 April 2002 Repka et al. 6395295 May 2002 Hills et al. 6395746 May 2002 Cagle et al. 6423333 July 2002 Stedronsky et al. 6423694 July 2002 Drutz et al. 6533749 March 2003 Mitusina et al. 6541116 April 2003 Michal et al. 6541460 April 2003 Petito 6610314 August 2003 Koenig et al. 6613084 September 2003 Yang 6616913 September 2003 Mautone 6623513 September 2003 Biel 6623521 September 2003 Steinke et al. 6632457 October 2003 Sawhney 6676930 January 2004 Mautone 6685697 February 2004 Arenberg et al. 6686346 February 2004 Nilsson et al. 6706290 March 2004 Kajander et al. 6723709 April 2004 Pressato et al. 6762160 July 2004 Barbeau et al. 6770729 August 2004 Van Antwerp 6812196 November 2004 Rees et al. 6855678 February 2005 Whiteley 6867233 March 2005 Roselle et al. 6869938 March 2005 Schwartz et al. 6891037 May 2005 Hasler et al. 6919348 July 2005 Wei 6936579 August 2005 Urban 6953772 October 2005 Lopes 6962813 November 2005 Pier et al. 6989195 January 2006 Anderson 7090882 August 2006 Koefod et al. 7119217 October 2006 Jiang et al. 7128897 October 2006 Osbakken et al. 7220431 May 2007 Sawchuk et al. 7238363 July 2007 Mansouri et al. 7244841 July 2007 Love et al. 7341983 March 2008 Pedersen et al. 7410480 August 2008 Muni et al. 7446089 November 2008 Singh et al. 7494963 February 2009 Ahmed et al. 7544192 June 2009 Eaton et al. 7714011 May 2010 Clarot et al. 7976875 July 2011 Myntti 8044156 October 2011 Tamareselvy et al. 8062246 November 2011 Moutafis et al. 2001/0044651 November 2001 Steinke et al. 2001/0051613 December 2001 Illum et al. 2002/0022588 February 2002 Wilkie et al. 2002/0029015 March 2002 Camenzind et al. 2002/0055158 May 2002 Greene et al. 2002/0187918 December 2002 Urban 2003/0009213 January 2003 Yang 2003/0062147 April 2003 Schoen et al. 2003/0079758 May 2003 Siegel et al. 2003/0083219 May 2003 Rees et al. 2003/0133883 July 2003 Finnegan et al. 2003/0139382 July 2003 Wall et al. 2003/0157687 August 2003 Greene et al. 2003/0199969 October 2003 Steinke et al. 2003/0235602 December 2003 Schwarz 2004/0101506 May 2004 Fust 2004/0106987 June 2004 Palasis et al. 2004/0110738 June 2004 Gillis et al. 2004/0116958 June 2004 Gopferich et al. 2004/0117006 June 2004 Lewis et al. 2004/0143001 July 2004 Love et al. 2004/0204399 October 2004 Oshbakken et al. 2004/0213758 October 2004 Sefton et al. 2004/0214753 October 2004 Britten et al. 2005/0003007 January 2005 Boix et al. 2005/0032668 February 2005 Pedersen et al. 2005/0042240 February 2005 Utterberg et al. 2005/0043706 February 2005 Eaton et al. 2005/0064508 March 2005 Belcher et al. 2005/0080396 April 2005 Rontal 2005/0106728 May 2005 Burgess et al. 2005/0147679 July 2005 Petito et al. 2005/0220895 October 2005 Bucalo et al. 2005/0226937 October 2005 O'Hagen et al. 2005/0244339 November 2005 Jauering et al. 2005/0282722 December 2005 McReynolds et al. 2006/0003008 January 2006 Gibson et al. 2006/0018945 January 2006 Britigan et al. 2006/0035808 February 2006 Ahmed et al. 2006/0045850 March 2006 Namburi et al. 2006/0051385 March 2006 Scholz 2006/0106361 May 2006 Muni et al. 2006/0205621 September 2006 Borazjani et al. 2006/0210605 September 2006 Chang et al. 2007/0207192 September 2007 Holl et al. 2007/0264226 November 2007 Karagoezian et al. 2007/0264310 November 2007 Hissong et al. 2007/0264342 November 2007 Oliver et al. 2007/0264353 November 2007 Myntti et al. 2008/0010947 January 2008 Huang et al. 2008/0248558 October 2008 Deinhammer et al. 2009/0005339 January 2009 Scholz et al. 2010/0240770 September 2010 Qi et al. 0 530 861 March 1993 1 374 856 January 2004 2 710 529 April 1995 52-007428 January 1977 2 125 432 January 1999 222 8203 May 2004 1128917 December 1984 1699430 December 1991 WO 92/16245 October 1992 WO 94/05330 March 1994 WO 95/03036 February 1995 WO 97/38698 October 1997 WO 98/09622 March 1998 WO 99/27905 June 1999 WO 00/21510 April 2000 WO 00/56283 September 2000 WO 03/061579 July 2003 WO 03/092745 November 2003 WO 2004/009143 January 2004 WO 2004/024187 March 2004 WO 2004/087227 October 2004 WO 2005/000029 January 2005 WO 2005/089670 September 2005 WO 2006/099386 September 2006 WO 2008/097317 August 2008 |
| Other References: | Gross CW, et al. 2001. Autologous Fibrin Sealant Reduces Pain After Tonsillectomy. The Laryngoscope; 111: 259-263. cited by examiner Post, J.C., “Direct evidence of bacterial biofilms in otitis media”, Laryngoscope 111(12):2083-94 (2001). cited by applicant Ehrlich et al., “Mucosal Biofilm Formation on Middle-Ear Mucosa in the Chinchilla Model of Otitis Media”, JAMA 287(13):1710-15 (2002). cited by applicant Fergie, N. et al., “Is otitis media with effusion a biofilm infection?”, Clin Otolaryngol Allied Sci. 29(1):38-46 (2004). cited by applicant Ferguson B.J. and Stolz D.B., “Demonstration of biofilm in human bacterial chronic rhinosinusitis”, Am J Rhinol 19:452-457, 2005. cited by applicant Ramadan H.H., Sanclement J.A. and Thomas J.G., “Chronic rhinosinusitis and biofilms”, Otolaryngol Head Neck Surg. 132:414-417, 2005. cited by applicant Benninger M.S., Ferguson B.J., Hadley J.A., et al., “Adult chronic rhinosinusitis: Definitions, diagnosis, epidemiology, and pathophysiology”, Otolaryngol Head Neck Surg 129 (3 suppl):S1-S32, 2003. cited by applicant Nadel D.M., Lanza D.C., and Kennedy D.W., “Endoscopically guided cultures in chronic sinusitis”, Am J Rhinol 12:233-241, 1998. cited by applicant Stepanovic S, Vukovic D, Dakic I, et al., “A modified microtiter-plate test for quantification of staphylococcal biofilm formation”, J Microbiol Methods 40:175-179, 2000. cited by applicant Gotz F., “Staphylococcus and biofilms”, Mol Microbiol 43:1367-1378, 2002. cited by applicant Lethbridge-ejku M, Rose D, Vickerie J. Summary health statistics for US adults: National Health Interview Survey, 2004. National Center for Health Statistics. Vital Health Stat 2006;10 (228). Available: http://www.cdc.gov/nchs/fastats/sinuses.htm. cited by applicant Rosiak, J.M. et al., “Radiation Formation of Hydrogels for Biomedical Purposes. Some Remarks and Comments”, Radiat. Phys. Chem. vol. 46, No. 2, pp. 161-168, 1995. cited by applicant Costerton J.W., Stewart P.S. and Greenberg E.P., “Bacterial biofilms: A common cause of persistent infections”, Science 284:1318-1322, 1999. cited by applicant Morris D.P. and Hagr A., “Biofilm: Why the sudden interest?” J Otolaryngol 34(suppl 2):S56-S5, 2005. cited by applicant Hall-Stoodley L, Hu F.Z., Gieseke A, et al., “Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media.” JAMA 296:202-211, 2006. cited by applicant Sanderson A.R., Leid J.G., and Hunsaker D., “Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis”, Laryngoscope 116:1121-1126 (2006). cited by applicant Sanclement J.A., Webster P., Thomas J., and Ramadan H.H., “Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis”, Laryngoscope 115:578-582, 2005. cited by applicant Bendouah Z., Barbeau J., Hamad W.A., and Desrosiers M., “Biofilm formation by Staphylococcus aureus and Pseudomonas aeruginosa is associated with an unfavorable evolution after surgery for chronic sinusitis and nasal polyposis”, Otolaryngol Head Neck Surg. 134:991-996, 2006. cited by applicant Bhattacharyya N., and Kepnes L.J., “The microbiology of recurrent rhinosinusitis after endoscopic sinus surgery”, Arch Otolaryngol Head Neck Surg. 125:1117-1120, 1999. cited by applicant Cryer J., Schipor I., Perloff J.R., and Palmer J.N., “Evidence of bacterial biofilms in human chronic sinusitis”, ORL J Otorhinolaryngol Relat Spec 66:155-158, 2004. cited by applicant Meltzer E.O., Hamilos D.L., Hadley J.A., et al., “Rhinosinusitis: Establishing definitions for clinical research and patient care”, J Allergy Clin Immunol 114(suppl):S155-S212, 2004. cited by applicant Chiu A.G., and Kennedy D.W., “Surgical management of chronic rhinosinusitis and nasal polyposis: a review of the evidence”, Curr Allergy Asthma Rep 4:486-489, 2004. cited by applicant Bhattacharyya N., “Clinical outcomes after endoscopic sinus surgery”, Curr Opin Allergy Clin Immunol 6:167-171, 2006. cited by applicant Wormald P.J., Psaltis A., and Ha K., “A sheep model for the study of biofilms in sinusitis”, In Programs and abstracts of the 52nd Annual Meeting of the American Rhinologic Society, Toronto, Ontario, Canada, Sep. 16, 2006. cited by applicant Anglen J.O., Apostoles S., Christensen G., and Gainor B., “The efficacy of various irrigation solutions in removing slime-producing Staphylococcus”, J Orthop Trauma 8:390-396, 1994. cited by applicant Chole, Richard A. and Faddis, Brian T., Evidence for Microbial Biofilms in Cholesteatomas, Arch Otolaryngol Head and Neck Surg. 2002; 128: 1129-1133. Downloaded Apr. 17, 2007 from Medtronic Xomed at www.archoto.com. cited by applicant Desrosiers M. Refractory chronic rhinosinusitis: pathophysiology and management of chronic rhinosinusitis persisting after endoscopic sinus surgery. Curr Allergy Asthma Rep 2004;4:200-7. cited by applicant Smith TL, Batra PS, Seiden AM, Hannley M. Evidence supporting endoscopic sinus surgery in the management of adult chronic sinusitis: a systematic review. Am J Rhinol 2005;19:537-43. cited by applicant Perloff JR, Palmer JN. Evidence of bacterial biofilms on frontal recess stents in patients with chronic rhinosinusitis. Am J Rhinol 2004;18:377-80. cited by applicant Wright ED, Frenkiel S. Infectious adult rhinosinusitis: etiology, diagnosis, and management principles. J Otolaryngol 2005;34(suppl 1):S7-13. cited by applicant Luong A, Marple BF. Sinus surgery: indications and techniques. Clin Rev Allergy Immunol 2006;30:217-22. cited by applicant Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 2206;27:196-200. cited by applicant Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2005;49:2467-73. cited by applicant Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003;47:317-23. cited by applicant Palmer JN. Bacterial biofilms: do they play a role in chronic sinusitis? Otolaryngol Clin N Am 2005;38:1193-1201. cited by applicant Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002;8:881-90. cited by applicant Potera C. Forging a link between biofilms and disease. Science 1999;283:1837, 1839. cited by applicant Post JC, Stoodley P, Hall-Stoodley L, Ehrlich GD. The role of biofilms in otolaryngologic infections. Curr Opin Otolaryngol Head Neck Surg 2004;12:185-90. cited by applicant Tonnaer EL, Graamans K, Sanders EA, Curfs JH. Advances in understanding the pathogenesis of pneumococcal otitis media. Pediatr Infect Dis J 2006;25:546-52. cited by applicant Rayner MG, Zhang Y, Gorry MC, Chen Y, Post CJ, Ehrlich GD. Evidence of bacterial metabolic activity in culture-negative otitis media with effusion. JAMA 1998;279:296-9. cited by applicant Dingman JR, Rayner MG, Mishra S, Zhang Y, Ehrlich MD, Post JC, et al. Correlation between presence of viable bacteria and presence of endotoxin in middle-ear effusions. J Clin Microbiol 1998;36:3417-9. cited by applicant Perloff JR, Palmer JN. Evidence of bacterial biofilms in a rabbit model of sinusitis. Am J Rhinol 2005;19:1-9. cited by applicant Chiu A, Antunes M, Feldman M, Cohen N. Dose-dependent effects of topical tobramycin in an animal model of Pseudomonas sinusitis. In: Programs and abstracts of the 52nd Annual Meeting of the American Rhinologic Society; Sep. 16, 2006; Toronto, ON, Canada. cited by applicant Witterick IJ, Kolenda J. Surgical management of chronic rhinosinusitis. Immunol Allergy Clin N Am 2004;24:119-34. cited by applicant Lieu JE, Piccirillo JF. Methodologic assessment of studies on endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 2003;129:1230-5. cited by applicant Lavigne F, Tulic MK, Gagnon J, Hamid Q. Selective irrigation of the sinuses in the management of chronic rhinosinusitis refractory to medical therapy: a promising start. J Otolaryngol 2004;33:10-16. cited by applicant Yamada et al., “Chitosan Based Water-Resistant Adhesive. Analogy to Mussel Glue”, Biomacromolecules 2000, 1 (2), pp. 252-258 (Apr. 13, 2000). cited by applicant “Protein Polymer Technologies Product Research” dated Mar. 28, 2006, 2 pages, downloaded from the Internet Archive at: http://web.archive.org/web/20060328113942/www.ppti.com/Market/Research.html. cited by applicant Gross, Charles W., et al., “Autologus Fibrin Sealant Reduces Pain After Tonsillectomy”, The Laryngoscope 111, pp. 259-263 (Feb. 2001). cited by applicant Kitajiri et al., “Relief of Post-Tonsillectomy Pain by Release of Lidocaine From Fibrin Glue”, The Laryngoscope 111, pp. 642-644 (Apr. 2001). cited by applicant Vaiman Michael et al., “Fibrin Sealant Reduces Pain After Tonsillectomy: Prospective Randomized Study”, Annals of Otology, Rhinology & Laryngology 115 (7), pp. 483-489 (2006). cited by applicant Archer, Sanford M. MD, Nasal Polyps, Nonsurgical Treatment, eMedicine, dated Oct. 19, 2004, downloaded from the Internet Archive at: http://web.archive.org/web/20041019082359/http://www.emedicine.com/ent/topic334.htm. cited by applicant Atridox®, Package insert and Carton Label Rev 7 (Feb. 2003). cited by applicant Kumar et al., “Inhibition of Inflammation and Roflumilast and Dexamethasone in Murine Chronic Asthma”, Journal of Pharmacology and Experimental Therapeutics, vol. 307, No. 1, pp. 349-355 (2003). cited by applicant CollaGenex Atridox® web page, dated Sep. 26, 2004, downloaded from the Internet Archive at: http://web.archive.org/web/20041205004132/collagenex.com/pr—atridox.asp. cited by applicant Lechapt-Zalcman et al., Increased expression of matrix metalloproteinase-9 in nasal polyps, Journal of Pathology, 193:233-241 (2001). cited by applicant Kyung, Lee S. et al., Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma, Journal of Allergy and Clinical Immunology [online] (May 2004). cited by applicant Watelet, J.B. et al., Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs. nasal polyposis, Allergy, 59:54-60 (2004). cited by applicant Plateltex, “Reduce fibrosis-Reducing scarring-Autologous Platelets”, accessed on Jan. 26, 2010 from: http://www.plateltex.com/lp—reduce—fibrosis.html. cited by applicant Stoeckli, Sandro J. et al., “A Prospective Randomized Double-Blind Trial of Fibrin Glue for Pain and Bleeding After Tonsillectomy”, Laryngoscope 109: pp. 652-655, (Apr. 1999). cited by applicant Granick Mark MD et al., “Toward a common language: surgical wound bed preparation and debridement”, Wound Repair and Regeneration, 14, S1-S10, © the Wound Healing Society, (2006). cited by applicant Stetter, Christopher et al., “Skin grafting of a chronic leg ulcer with combined Versajet™—V.A.C. therapy”, XP-002566870 Case Reports, JDDG, 4:739-742 (2006). cited by applicant Nagoba, B.S. et al., A Simple and Effective Approach for the Treatment of Chronic Wound Infections Caused by Multiple Antibiotic Resistant Escherichia coli, Journal of Hospital Infection, 69:177-180 (2008). cited by applicant Banin, Ehud et al., “Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in a Biofilm”, Applied and Environmental Microbiology, vol. 72, No. 3, pp. 2064-2069 (Mar. 2006). cited by applicant Chang, D.M., The Binding of Free Calcium Ions in Aqueous Solution Using Chelating Agents, Phosphates and Poly (Acrylic Acid), JAOCS, vol. 60, No. 3, pp. 618-622 (Mar. 1983). cited by applicant “Medicine Encyclopedia” M., RLS, Miramistin solution 0.01%, p. 561 ( 2001). cited by applicant Ambrose et al., “In Vitro Studies of Water Activity and Bacterial Growth Inhibition of Sucrose-Polyethylene Glycol 400-Hydrogen Peroxide and Xylose-Polyethylene Glycol 400-Hydrogen Peroxide and Xylose-Polyethylene Glycol 400-Hydrogen-Peroxide Pastes Used to Treat Infected Wounds”, Antimicrob Agents Chermo, vol. 35, No. 9, pp. 1799-1803 (Sep. 1991). cited by applicant Sigma-Aldrich Company, Product No. F3879 Fibrinogen Product Information Sheet (2002). cited by applicant Sigma-Aldrich Company, Product No. T4648 Product Information Sheet (2009). cited by applicant Sigma-Aldrich Company, Product No. F3879 Fibrinogen Product Specification (2011). cited by applicant Sigma-Aldrich Company, Product No. 419338 Product Specification (2012). cited by applicant Sigma-Aldrich Company, Product No. T4648 Product Specification (2013). cited by applicant Stedman's Medical Dictionary, 24th Edition, pp. 1292-1294 (1983). cited by applicant Phillips, P. et al., “Bacterial Biofilms in wounds”, Wound Healing Southern Africa, vol. 1, No. 2, pp. 10-12 (2008). cited by applicant Pitten et al., “Efficacy of Cetylpyridinium Chloride Used as Oropharyngeal Antiseptic”, Arzneimittelforschung/Drug Research 51, 7 pp. 588-595 (Jul. 2001). cited by applicant Birnie et al.,“Antimicrobial Evaluation of N-Alkyl Betaines and N-Alkyl-N,N-Dimethylamine Oxides with Variations in Chain Length”, Antimicrobial Agents and Chemotherapy, 44 (9), pp. 2514-2517 (Sep. 2000). cited by applicant Birnie et al., “Antimicrobial and Diffusional Correlation of N-Alkyl Betaines and N-Alkyl-N,N-Dimethylamine Oxides From Semisolids”, Journal of Pharmaceutical Sciences, 90 (9), pp. 1386-1394 (Sep. 2001). cited by applicant Steinberg et al., “Testing a Degradable Topical Varnish of Cetylpyridinium Chloride in an Experimental Dental Biofilm Model”, Journal of Antimicrobial Chemotherapy, 48 (2), pp. 241-24 (Aug. 2001). cited by applicant Harrington et al., “Antimicrobial Activity of Gallium against Virulent Rhodococcus equi In Vitro and In Vivo”, Journal of Veterinary Pharmacology and Therapeutics, 29 (2), pp. 121-127 (Apr. 2006). cited by applicant Stojiljkovic et al., “Non-Iron Metalloporphyrins: Potent Antibacterial Compounds That Exploit haem/Hb Uptake Systems of Pathogenic Bacteria”, Molecular Microbiology, 31 (2), pp. 429-442 (Jan. 1999). cited by applicant “Traditional Amine Oxides” BU ICS, Industrial & Home Care, Clariant, Inc. newsletter, Issue 8, pp. 1-7 (Aug. 2010). cited by applicant Corner, A.M. et al., “C31G, a New Agent for Oral Use with Potent Antimicrobial and Antiadherence Properties”, Antimicrobial Agents and Chemotherapy, vol. 32, No. 3, pp. 350-353 (Mar. 1988). cited by applicant Datsenko B.M., Theory and practice of topical treatment of chronic festering wounds (Problems of therapy using medications), 3 pages (1995). cited by applicant |
| Assistant Examiner: | Browe, David |
| Primary Examiner: | Azpuru, Carlos |
| Attorney, Agent or Firm: | IPLM Group, P.A. |
| رقم الانضمام: | edspgr.09119896 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |